XPC-6444

N/A

Report date: 2025/01/26 15:36:54
NME

Base Information

Drug NameXPC-6444
Drug Alias Namedual NaV1.6/1.2 antagonist (Xenon Pharmaceuticals/Schrodinger/Icahn School of Medicine)XPC-6444
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type II alpha subunit blockersSodium channel protein type VIII alpha subunit blockers
TargetsSodium channel protein type VIII alpha subunitSodium channel protein type II alpha subunit
Therapy Area/IndicationsEpilepsy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXenon Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMount Sinai Medical Center/Miami Jewish Home Andhospital For Theed Home HealthencySchrodinger IncXenon Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsEpilepsy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A